Zobrazeno 1 - 10 of 43 pro vyhledávání: '"M J, Weinstein"'
1
Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays
Autor: Joseph W Jackson, M J Weinstein, Dorothy E. Scott, Mikhail V Ovanesov, Leonid A. Parunov, Samuel A. Woodle, Timothy K Lee, Yideng Liang, Stepan S Surov
Publikováno v: Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 211-222 (2021)
Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa‐like pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1c222c4217df1a21ef8507b1bf991d
https://doi.org/10.1002/rth2.12467
Zobrazit plný text záznamu
2
Considerations of pool size in the manufacture of plasma derivatives
Autor: M J Weinstein, Joseph C. Fratantoni, D L Tankersley, J.S. Finlayson, T J Lynch
Publikováno v: Transfusion. 36:770-775
Background The pooling of human plasma from many donors for the purpose of manufacturing therapeutic proteins increases the risk of exposing recipients of these proteins to pathogens that may contaminate 1 or a few units included in the pool. Study d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2068571f15fbc55600fe421777aafc
https://doi.org/10.1046/j.1537-2995.1996.36996420751.x
Zobrazit plný text záznamu
3
Fibrin sealant: summary of a conference on characteristics and clinical uses
Autor: Barbara M. Alving, Joseph C. Fratantoni, M J Weinstein, J E Menitove, J.S. Finlayson
Publikováno v: Transfusion. 35:783-790
The 2-day conference clearly outlined the formulations of products that are being developed or are commercially available in Europe. The major difference between products in the United States and those in Europe is that US manufacturers are preparing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eb5ebef7f2a4791c021e011a9aced35
https://doi.org/10.1046/j.1537-2995.1995.35996029166.x
Zobrazit plný text záznamu
4
Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma
Autor: J, Berg, M J, Weinstein, D S, Springfield, W M, Rand
Publikováno v: Journal of the American Veterinary Medical Association. 206(10)
Thirty-five dogs with appendicular osteosarcoma were treated with 5 doses of doxorubicin (30 mg/m2 of body surface, i.v., every 2 weeks). Surgical excision of the primary tumor was performed 13 days after the second (n = 18) or third (n = 17) treatme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::324ec843042f574a7ff6dc44a7ff3068
https://pubmed.ncbi.nlm.nih.gov/7775232
Zobrazit plný text záznamu
7
Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990)
Autor: J, Berg, M J, Weinstein, S H, Schelling, W M, Rand
Publikováno v: Journal of the American Veterinary Medical Association. 200(12)
Twenty-two dogs with appendicular osteosarcoma were treated by amputation (n = 17) or limb-sparing surgery (n = 5). All dogs were given cisplatin (60 mg/m2 of body surface, IV) at 3-week intervals, beginning 1 week after surgery. Number of cisplatin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::03152ce78584c58caa8729a7525f2eb8
https://pubmed.ncbi.nlm.nih.gov/1639715
Zobrazit plný text záznamu
8
In vitro assay of nuclear uptake of doxorubicin hydrochloride in osteosarcoma cells of dogs
Autor: M J, Weinstein, J, Berg, K, Kusuzaki, D S, Springfield, M C, Gebhardt, H J, Mankin
Publikováno v: American journal of veterinary research. 52(12)
A rapid, simple chemosensitivity assay, assessing tumor cell nuclear uptake of doxorubicin hydrochloride, was evaluated in 16 dogs with appendicular osteosarcoma. Doxorubicin was administered to dogs in 5 biweekly treatments, and surgical resection w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0f54d970cf5486d81b62401bb4d19519
https://pubmed.ncbi.nlm.nih.gov/1789508
Zobrazit plný text záznamu
9
Apparent molecular weight of purified human factor VIII procoagulant protein compared with purified and plasma factor VIII procoagulant protein antigen
Autor: M J, Weinstein, C A, Fulcher, L E, Chute, T S, Zimmerman
Publikováno v: Blood. 62:1114-1117
We have compared apparent molecular weights of purified factor VIII procoagulant protein (VIII:C) and VIII:C antigen (VIII:CAg) by two different NaDodSO4 gel electrophoretic techniques. In a discontinuous NaDodSO4–7.5% polyacrylamide system, reduce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e5a326a20114e004ef3b552efc7a5e
https://doi.org/10.1182/blood.v62.5.1114.bloodjournal6251114
Zobrazit plný text záznamu
10
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation
Autor: G W Schmitt, J H Troll, L E Chute, M J Weinstein, Kenneth A. Bauer, R H Hamburger, Daniel Deykin, Janson Pa
Publikováno v: Journal of Clinical Investigation. 76:1406-1411
Factor VIII antigen (VIII:CAg) exhibits molecular weight heterogeneity in normal plasma. We have compared the relative quantities of VIII:CAg forms present in normal individuals (n = 22) with VIII:CAg forms in renal dysfunction patients (n = 19) and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a87489becc3d787328a13ce49d4253c0
https://doi.org/10.1172/jci112117
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje